GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » Quality Rank

Stayble Therapeutics AB (STU:4K4) Quality Rank


View and export this data going back to 2022. Start your Free Trial

What is Stayble Therapeutics AB Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Stayble Therapeutics AB Quality Rank Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB (STU:4K4) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » Quality Rank
Comparable Companies
OSTO:ACTI XSAT:HAMLET B OSTO:SPRINT OSTO:ISOFOL OSTO:ABLI OSTO:ELIC OSTO:ALZ OSTO:BIOVIC B OSTO:NXTCL OSTO:BIOWKS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
STABL:Sweden 4K4:Germany
Address
Medicinaregatan 8a, Gothenburg, SWE, SE-413 90
Website
http://www.staybletherapeutics.com
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.